logo
  

Ionis Says Partner Roche Licenses And Advances Rare Kidney Disease Treatment Into Phase 3 Trial

Ionis Pharmaceuticals, Inc. (IONS) announced Monday that its long-standing partner, Roche, will license and advance IONIS-FB-LRx, an investigational antisense medicine, into a Phase 3 clinical study in patients with immunoglobulin A nephropathy (IgAN).

Roche's decision to advance the program comes after positive data from a Phase 2 clinical study in which IONIS-FB-LRx met its primary endpoint of change in 24-hour urinary protein at 29 weeks compared to baseline.

Roche will lead and be responsible for the Phase 3 study of IONIS-FB-LRx in patients with IgAN and for future global development, regulatory and commercialization activities.

IgAN is a rare and serious condition that often leads to chronic kidney disease and renal failure. It occurs when too much IgA protein accumulates in the kidneys, causing inflammation and tissue damage, which is the root cause of the disease.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
North Korea fired a long-range ballistic missile over Japan, evoking international condemnation. The unprovoked surprise launch Tuesday morning did not cause any harm, and the missile fell into the Pacific Ocean, reports said. The missile reportedly covered 4,600 kilometers - a distance enough to target the American island of Guam in the Pacific. This marks Pyongyang's first missile launch over Hospitality company Hilton has teamed with connected fitness platform Peloton Interactive, Inc. to feature Peloton Bikes across its entire U.S. hotel portfolio. In an industry-first partnership, Hilton's nearly all 5,400 U.S. Hilton-branded hotels will feature at least one Peloton Bike in every fitness center by the end of the year. Australia's central bank raised its benchmark rate by a smaller-than-expected quarter point on Tuesday, after lifting rates by 50 basis points in each of the last four meetings. The policy board of the RBA, headed by Governor Philip Lowe, decided to lift the cash rate target by 25 basis points to 2.60 percent from 2.35 percent. This was the highest rate since July 2013.
Follow RTT